SGLT2 inhibitors: Hot Topics and Challenges

Moderator(s)

• 

  Guillermo Umpierrez, MD, MACP, CDCES, FACE

  Professor of Medicine
  Emory University
  Atlanta, GA, United States

  Astra Zeneca (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Dexcom (Self) : University Grants/Research Support (Status: Ongoing); Novo Nordisk (Self) : Grant support to Emory University for investigator-initiated clinical studies (Status: Terminated --- December 2020), University Grants/Research Support (Status: Terminated --- December 2020); Sanofi,Merck, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim (Self) : Received grant support (to Emory university) for investigator-initiated research studies from Sanofi, Novo Nordisk, Astra Zeneca, Merck and Boehringer Ingelheim. (Status: Terminated --- January 2019), Research Grant (Status: Terminated --- January 2019)

Presentations:

• 1:00 PM – 1:20 PM

  Use of SGLT2 Inhibitors in the Inpatient Setting
  

  Speaker: Roma Gianchandani, MBBS – Cedars Sinai Health System
• 1:20 PM – 1:40 PM

  The Efficacy and Risks of SGLT2 Inhibitors
  

  Speaker: Neda Rasouli, MD – University of Colorado
• 1:40 PM – 2:00 PM

  Collaboration with Non-Endocrinologists Using SGLT2 Inhibitors for Non-Diabetes Indications
  

  Speaker: Kristen Kulasa, MD – University of California San Diego Health